Study of tofacitinib for immune function in Down syndrome
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study tests if an oral medication called tofacitinib can help the immune system work better in children and young adults with Down syndrome, which may improve learning and development. The study will follow participants for 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have Down syndrome.
- Be between the ages of 6 and 22.
- Weigh at least 22 pounds (10 kg).
- Must not have taken a JAK inhibitor or had certain other treatments recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how the immune system changes over time in people with Down syndrome, and how it may be affected by removal of the thymus gland. The goal is to understand why people with Down syndrome may age faster or have different immune health.
This trial tests whether the drug tofacitinib can help people with ALS by calming an overactive immune system. You’ll need a genetic test to see if your immune profile matches what the study is looking for.
This study tests if an investigational drug called AEF0217 can help improve thinking and daily living skills in people with Down syndrome. It's for ages 16-32 who have a caregiver to support them throughout the trial.
This study tests a drug called ublituximab, given as an IV infusion, for adults with Down syndrome who have developed regression disorder and haven't fully improved with standard treatments. The goal is to see if this treatment can help improve daily functioning and quality of life.
This trial studies the use of a medication called tofacitinib in children and teenagers with juvenile idiopathic arthritis (JIA), a type of arthritis that starts in childhood. The goal is to see if the drug helps reduce joint pain and inflammation.
This study tests the safety of a daily pill called Tofacitinib for adults with mild-to-moderate Sjögren's disease. It aims to see if this drug helps manage symptoms when other treatments haven't worked well.
Hear when a new Down Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.